SAN DIEGO, Sept. 30, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that it has
appointed George J. Morrow to its
Board of Directors. Mr. Morrow has over three decades of global
pharmaceutical commercial operations leadership experience with
Amgen, Glaxo Wellcome, and Merck. He was most recently the
Executive Vice President, Global Commercial Operations at
Amgen.
"We are excited to welcome George
Morrow to the Board of Directors," said William H. Rastetter, Chairman of the Board of
Neurocrine Biosciences. "His extensive commercial background and
the knowledge and expertise he has gained from leading global
pharmaceutical companies will be an invaluable resource as
Neurocrine continues its evolution into a commercial
organization."
Mr. Morrow served as Executive Vice President, Global Commercial
Operations at Amgen Inc., a global biotechnology company, from 2003
until his retirement in 2011. He joined Amgen in
2001 as Executive Vice President, Worldwide Sales and Marketing.
His responsibilities included oversight of all commercial functions
for Amgen's broad spectrum of products in more than 50
countries worldwide, and the introduction of multiple new products
into global markets. From 1992 to 2001, Mr. Morrow held executive
management and commercial positions within several subsidiaries of
Glaxo Wellcome, including Group Vice President for Commercial
Operations (U.S.), Managing Director (U.K.), and most recently as
President and Chief Executive Officer of Glaxo Wellcome,
Inc. (U.S.).
Mr. Morrow currently serves on the board of directors of
Otonomy, Inc., a biotechnology company, Vical, Inc., a
biotechnology company and Align Technology, Inc., a global medical
device company. He has previously served on the boards of Glaxo
Wellcome, Inc., Human Genome Sciences, Inc., Safeway, Inc.,
National Commerce Bank, the John Hopkins School of Public Health,
and the Duke University Fuqua School of
Business. Mr. Morrow holds a B.S. in chemistry from Southampton College, Long
Island University, an M.S. in biochemistry from Bryn Mawr College and an M.B.A. from Duke University.
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial
rights to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-appointment-of-george-j-morrow-to-its-board-of-directors-300151883.html
SOURCE Neurocrine Biosciences, Inc.